English
Structure via PubChem · Public domain (PubChem)
dexelvucitabine
Sign in to saveDexelvucitabine is a failed experimental agent for the management of human immunodeficiency virus infection. It is a cytidine nucleoside analog and nucleoside reverse transcriptase inhibitor. that inhibits HIV-1 replication in vitro. During phase II clinical trials there was some indication of a decreased mean viral load in patients with infected human immunodeficiency virus.
Chemical data
- Formula
- C9H10FN3O3
- Molecular weight
- 227.19 g/mol
- IUPAC name
- 4-amino-5-fluoro-1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
- SMILES
- C1=C[C@@H](O[C@@H]1CO)N2C=C(C(=NC2=O)N)F
- InChIKey
- HSBKFSPNDWWPSL-CAHLUQPWSA-N
- XLogP
- -1.3
- Polar surface area
- 88.2 Ų
- H-bond donors
- 2
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- HIV infection
via ChEMBL · EBI
Research
39 papers- New drugs.HIV medicine · 2005
- Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine.Antimicrobial agents and chemotherapy · 2007
- Selection and characterization of HIV-1 with a novel S68 deletion in reverse transcriptase.Antimicrobial agents and chemotherapy · 2011
- ACH-126443 Achillion/Yale University.Current opinion in investigational drugs (London, England : 2000) · 2002
- Doubling spectroscopy challenge.Analytical and bioanalytical chemistry · 2015
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 227.071
Show 5 more facts
- stereoisomer of
- elvucitabine
- canonical SMILES
- C1=CC(OC1CO)N2C=C(C(=NC2=O)N)F
- chemical formula
- C₉H₁₀FN₃O₃
- isomeric SMILES
- C1=C[C@@H](O[C@@H]1CO)N2C=C(C(=NC2=O)N)F
- Commons category
- Dexelvucitabine
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Dexelvucitabine is a failed experimental agent for the management of human immunodeficiency virus infection. It is a cytidine nucleoside analog and nucleoside reverse transcriptase inhibitor. that inhibits HIV-1 replication in vitro. During phase II clinical trials there was some indication of a decreased mean viral load in patients with infected human immunodeficiency virus.
On April 3, 2006, Pharmasset and Incyte, the pharmaceutical companies developing dexelvucitabine, announced the decision to cease further trials and development of the drug due to an increased incidence of grade 4 hyperlipasemia (an excess of the pancreatic enzyme lipase in the bloodstream) in a phase II trial.
Excerpted from Wikipedia’s “dexelvucitabine” article, available under the CC BY-SA 4.0 licence.